These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15868023)

  • 21. Dengue immune response: low affinity, high febrility.
    Welsh RM; Rothman AL
    Nat Med; 2003 Jul; 9(7):820-2. PubMed ID: 12835692
    [No Abstract]   [Full Text] [Related]  

  • 22. [Advances in the development of a vaccine against dengue].
    Guzmán MG
    Acta Cient Venez; 1998; 49 Suppl 1():38-45. PubMed ID: 10030053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A re-evaluation of the mechanisms leading to dengue hemorrhagic fever.
    Noisakran S; Chokephaibulkit K; Songprakhon P; Onlamoon N; Hsiao HM; Villinger F; Ansari A; Perng GC
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E24-35. PubMed ID: 19751399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of dengue virus diseases: missing pieces in the jigsaw.
    Bielefeldt-Ohmann H
    Trends Microbiol; 1997 Oct; 5(10):409-13. PubMed ID: 9351178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T
    Curr Opin Mol Ther; 2004 Aug; 6(4):443-50. PubMed ID: 15468603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue is a major global health problem. Foreword.
    Singhasivanon P; Jacobson J
    J Clin Virol; 2009 Oct; 46 Suppl 2():S1-2. PubMed ID: 19800558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in understanding dengue virus replication.
    Urcuqui-Inchima S; Patiño C; Torres S; Haenni AL; Díaz FJ
    Adv Virus Res; 2010; 77():1-39. PubMed ID: 20951868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue vaccines for travelers.
    Wilder-Smith A; Deen JL
    Expert Rev Vaccines; 2008 Jul; 7(5):569-78. PubMed ID: 18564012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.
    Guzman MG; Alvarez M; Halstead SB
    Arch Virol; 2013 Jul; 158(7):1445-59. PubMed ID: 23471635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a dengue vaccine: progress to date and remaining challenges.
    Guy B; Almond JW
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):239-52. PubMed ID: 17889365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
    Raja NU; Holman DH; Wang D; Raviprakash K; Juompan LY; Deitz SB; Luo M; Zhang J; Porter KR; Dong JY
    Am J Trop Med Hyg; 2007 Apr; 76(4):743-51. PubMed ID: 17426182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T lymphocyte responses to heterologous secondary dengue virus infections.
    Rothman AL
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E36-41. PubMed ID: 19751400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development in the analysis of the pathogenesis of dengue hemorrhagic fever, and current status of dengue vaccine].
    Kurane I
    Uirusu; 2002 Jun; 52(1):15-20. PubMed ID: 12227165
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue vaccine: opportunities and challenges.
    Hatch S; Mathew A; Rothman A
    IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner.
    Beaumier CM; Mathew A; Bashyam HS; Rothman AL
    J Infect Dis; 2008 Feb; 197(4):608-17. PubMed ID: 18275279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Emergence of dengue hemorrhagic fever in the Americas. Reemergence of dengue].
    Guzmán Tirado MG; Kourí Flores G; Bravo González JR
    Rev Cubana Med Trop; 1999; 51(1):5-13. PubMed ID: 10887549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A travel medicine view of dengue and dengue hemorrhagic fever.
    Meltzer E; Schwartz E
    Travel Med Infect Dis; 2009 Sep; 7(5):278-83. PubMed ID: 19747662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.